Related Experiment Video

Updated: Jun 28, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

[Heart failure. Neurohormonal treatment]

Jesús Martínez Reding1

  • 1Hospitalización, Instituto Nacional de Cardiología "Ignacio Chávez", INCICH, Juan Badiano Núm. 1, Col. Sección XVI, Tlalpan 14080, México, DF.

Archivos De Cardiologia De Mexico
|October 22, 2008
PubMed

Insights

Neurohormonal overactivity contributes to heart failure (HF). Angiotensin-II blockage is a primary treatment, while natriuretic peptides offer potential for decompensated HF patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Physiology

Context:

  • Heart failure (HF) pathogenesis involves hemodynamic and neurohormonal factors.
  • Neurohormonal hypothesis implicates overactive endogenous endocrine systems.
  • Renin-angiotensin-aldosterone and autonomic systems are key neurohormonal pathways in HF.

Purpose:

  • To review the neurohormonal hypothesis of heart failure.
  • To discuss the therapeutic implications of targeting neurohormonal systems.
  • To highlight the role of natriuretic peptides in HF management.

Summary:

  • Angiotensin-II blockade is a leading therapy for HF, reducing cardiac remodeling and improving endothelial function.
  • Beta-adrenergic blockers precede Angiotensin-II blockade in HF treatment protocols.
  • Atrial myocardium releases natriuretic peptides (e.g., Peptide B) upon stretching, showing utility in decompensated HF.

Impact:

  • Understanding neurohormonal mechanisms refines HF treatment strategies.
  • Targeting specific pathways like Angiotensin-II offers significant clinical benefits.
  • Discovery of natriuretic peptides opens avenues for specialized HF therapies.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...